Carminomycin, 14-Hydroxycarminomycin and Its Novel Carbohydrate Derivatives Potently Kill Human Tumor Cells and Their Multidrug Resistant Variants
| Autor: | Eugenia N. Olsufyeva, Alexander A. Shtil, Valeria S. Simonova, Anna N. Tevyashova, Maria N. Preobrazhenskaya, A. V. Samusenko |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
ATP Binding Cassette Transporter
Subfamily B medicine.drug_class Cell Survival Antibiotics Breast Neoplasms Structure-Activity Relationship chemistry.chemical_compound Hydrolysis Drug Discovery Tumor Cells Cultured medicine Humans Melibiose Pharmacology Antibiotics Antineoplastic Leukemia Carubicin Wild type General Medicine Carbohydrate medicine.disease Drug Resistance Multiple Multiple drug resistance chemistry Biochemistry Drug Resistance Neoplasm Female Drug Screening Assays Antitumor Genes MDR Breast carcinoma K562 cells |
| Zdroj: | The Journal of Antibiotics. 57:143-150 |
| ISSN: | 1881-1469 0021-8820 |
| DOI: | 10.7164/antibiotics.57.143 |
| Popis: | The new hydrophilic derivatives of 14-hydroxycarminomycin were obtained using 13-dimethyl ketal of 14-bromocarminomycin (6) as the starting compound. The reductive alkylation of 6 with melibiose or D-galactose followed by hydrolysis of the corresponding intermediate bromoketals 9 and 11 produced 3'-N-[-alpha-D-(galactopyranosyl-(1 --6)-O-D-1-desoxyglucit-1-yl]-14-hydroxycarminomycin (10) and 3'-N-(1-desoxy-D-galactit-1-yl)-14-hydroxycarminomycin (12), respectively. These novel derivatives 10 and 12 were less toxic than carminomycin or 14-hydroxycarminomycin for leukemia (K562) and breast carcinoma (MCF-7) cells. Importantly, carminomycin, 14-hydroxycarminomycin and compounds 10 and 12 were similarly active for wild type cells and their multidrug resistant (MDR) sublines, K562i/S9 and MCF-7Dox. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|